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Background: Chronic rhinosinusitis (CRS) is a societal burden and cause of morbidity in Canada; however, the
prevalence of allergic sensitization in Canadian CRS patients has remained poorly characterized.
Objective: In this study, we used skin prick test (SPT) and specific immunoglobulin E (sIgE) and G (sIgG) titers to
regionally relevant allergen sources in order to determine whether allergic sensitization is more prevalent in CRS
patients compared to chronic idiopathic urticaria (CIU) control patients.
Methods: One hundred and fifty eight subjects (19–70 years of age) were recruited into the study. 101 subjects
had a confirmed diagnostic history of CRS and 57 subjects with a clinical diagnosis of CIU were recruited as
controls. Enrolled subjects underwent SPT to a panel of perennial and seasonal allergens and sIgE titers were
quantified to selected environmental allergen mixes (grass, mold, and tree species) using Phadia ImmunoCAP. sIgG
was additionally quantified to Alternaria alternata, Aspergillus versicolor, Cladosporium herbarum, and Stachybotrys
atra. Differences between CRS and control CIU patient SPT and serological data were examined by chi-squared
analysis and analysis of variance.
Results: Reactivity to at least one SPT extract occurred in 73% of CRS patients. Positive SPT reactivity to A. alternata
(odds ratio (OR): 4.34, 95% confidence interval: 1.57, 12.02), cat (OR: 3.23, 95% CI: 1.16, 9.02), and ragweed (OR: 2.31,
95% CI: 1.02, 5.19) extracts were more prevalent in patients with CRS (p < 0.05). Although dust mite and timothy
grass sensitization approached statistical significance in the chi-squared analysis of SPT data, other common
perennial and seasonal allergens were not associated with CRS. No statistically significant differences were observed
between mean sIgE and sIgG titers in CRS and control patients.
Conclusions: This study supports previous data that suggests A. alternata sensitization is associated with CRS;
however, these findings additionally highlight the contribution of other regionally important allergens including cat
and ragweed.
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Chronic rhinosinusitis (CRS) is characterized by inflam-
mation of the nasal mucosa and one or more paranasal si-
nuses for temporal intervals extending 8–12 weeks [1-3].
In Canada, CRS is an increasing public health burden and
accounted for approximately 3 million dispensed prescrip-
tions in 2006 [4,5]. Several Canadian epidemiological* Correspondence: zec1@cdc.gov
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approximately 5% of the general population [5,6]. In
those studies, the prevalence of CRS was higher in
women compared to men and eastern provinces had the
highest prevalence of CRS [5,6]. In Canada, like the
United States, CRS causes significant morbidity and re-
duced workplace productivity [2,5,7]. In the National
Population Health Survey, Canadian survey participants
that were identified with CRS had a self-perceived health
status comparable to participants with other chronic con-
ditions such as cancer, arthritis, asthma and inflammatory
bowel disease [5]. A reduction in the mental health oftd. This is an Open Access article distributed under the terms of the Creative
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sociated with a higher prevalence of depression, anti-
depressant use, and number of visits to mental health
professionals [5]. These results highlight the emerging
societal burden of CRS; however, fewer studies have
characterized the allergic sensitizations associated with
cases of CRS in Canada.
Studies of CRS etiology have shown that a progressive
accumulation of mucus can result in remodeling and
obstruction of the sinus ostia, bone erosion, facial pain,
swelling, and can co-occur with or without polyp for-
mation [1]. Although CRS may have an infectious or
non-infectious basis [1,8], allergic sensitization has been
suggested in several studies as an important contribut-
ing factor to the underlying pathology [3,6,9-11]. Total
IgE levels have been shown to correlate with the extent
of CRS disease on sinus CT [12]. Inflammation, swelling
and decreased mucociliary clearance associated with
allergic rhinitis and eosinophilic inflammation have been
postulated to enhance paranasal sinus ostia destruction
[6,9,10]. This pathology may increase the risk of CRS de-
velopment in sensitized patients but to date, the role of al-
lergens and allergic sensitization remains uncharacterized
and requires further clinical evaluation.
The coexistence of allergic rhinitis and CRS has been
previously reported in the literature [9,10,13,14] includ-
ing in a Canadian study [6]. The prevalence of allergic
sensitization has been reported to be as high as 84% in pa-
tients with CRS [9,13] and a major subset of this patient
group can be sensitized to more than one allergen [9].
Perennial allergen sensitization is more prevalent in CRS
patients [14] with dust mite and mold allergens among the
most frequently reported sensitizing sources [9,14]. The
role of fungi in CRS has been the focus of many research
studies as these microbial contaminants are commonly re-
covered from eosinophilic/allergic mucin. The association
with fungi has been controversial but is sometimes de-
scribed as mediating host immune reactions leading to the
development of CRS [8,15]. Despite these experimental
findings, the contribution of fungi and other perennial aller-
gens to CRS in Canada has remained poorly characterized.
In this study, we document the prevalence of allergic
sensitization to a selection of regionally prevalent peren-
nial and seasonal allergen sources in a cohort of Canadian
CRS patients. In addition, we compare the prevalence of
allergic sensitization to a wider panel of fungi implicated
in CRS. The identification of allergic sensitization to re-
gionally prevalent allergens may be an additional diagnos-
tic marker of CRS in clinical populations.
Materials and methods
Human subjects
One hundred and fifty eight study participants from the
Toronto metropolitan area (19–70 years of age) wererecruited into the study. One hundred and one subjects
were diagnosed with a history of CRS and 57 subjects
were recruited as controls with chronic spontaneous
urticaria (CIU). These study participant numbers were
not based on a sample size calculation. CRS was physician
diagnosed by physical exam based on the following symp-
tomology: sinus congestion or fullness; facial pain, pres-
sure or fullness; nasal obstruction or blockage; purulent
anterior or posterior nasal drainage; and decrease sense of
smell [16]. All CRS patients had endoscopy and CT scans
confirming diagnosis of CRS. CIU is generally considered
a non-IgE mediated disease and physician diagnosed
patients were recruited to the control population as a
way to control for confounding variables. When pos-
sible, consecutive patients presenting to the clinic were
recruited to this study.
Enrolled subjects underwent skin prick testing (SPT)
and were asked to provide a blood sample by venipuncture
(20 mL) for serological analysis of specific immunoglobu-
lin E (sIgE) and G (sIgG). Human serum was separated
in vitro from the collected blood samples and then trans-
ferred to the National Institute for Occupational Safety
and Health (NIOSH) and stored at −80°C until serological
analysis. This study was approved by the NIOSH Human
Subject Review Board (05-HELD-04XP) and the Ontario
Institutional Review Board Services. Informed consent
was obtained from all participants.
Skin prick testing
The panel of SPT extracts comprised a variety of perennial
(cat, dog, dust mite, cockroach and mouse), grass/weed
(june, orchard, sweet timothy, cocklebur and ragweed),
tree (ash, black birch, elm, maple, oak, pine, poplar and
willow) and fungal allergens (Alternaria alternata, Asper-
gillus flavus, Cephalosporium, Cephalothecium, Fusarium,
Helminthosporium, Hormodendrum, Monilia sitophila,
Mucor, Penicillium, Phoma, and Rhizopus) from ALK
(Hørsholm, Denmark). SPTs were performed by pla-
cing a drop of test solution on the skin and pricking
the epidermis beneath the drop with a disposable plastic
lancet (J.N. Eberle GmbH Hochfeldrasse 6–8 D-86830
Schwabmuenchen, Germany). SPT sites were wiped clean
and after fifteen minutes, the wheal and flare reactions
were outlined and the diameters measured. Histamine
(10 mg/mL) was used as a positive control and diluent
(HSA in 50% glycerol) was used as a negative control. A
positive reaction was characterized as 3 mm or greater
than that of the negative control.
Serological analysis
Serological quantification of sIgE and sIgG titers was con-
ducted by fluoroenzyme immunoassay using a Phadia
ImmunoCAP 100 (Phadia AB, Uppsala, Sweden). sIgE was
quantified to selected environmental allergens using a sIgE
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trees (tx1). The grass mix (gx1) was comprised of Dactylis
glomerata (g3), Festuca elatior (g4), Lolium perenne (g5),
Phleum pratense (g6), and Poa pratense (g8). The mold
mix (mx2) was comprised of Penicillium chrysogenum
(m1), Cladosporium herbarum (m2), Aspergillus fumigatus




n n pos %pos n n
Perennial
Cat 99 29 29.29 44
Dust Mite 99 29 29.29 44
Dog 99 13 13.13 44
Cockroach 99 0 0 44
Mouse 99 0 0 44
Seasonal
Ragweed 99 40 40.40 44
June 99 30 30.30 19
Black Birch 99 21 21.21 44
Timothy 99 19 19.19 43
Orchard 99 19 19.19 19
Sweet 99 19 19.19 19
Ash 99 16 16.6 20
Cocklebur 99 10 10.10 19
Maple 99 9 9.09 20
Willow 99 7 7.07 20
Oak 99 7 7.07 20
Poplar 99 5 5.05 20
Elm 99 4 4.04 20
Pine 99 2 2.02 20
Fungal
Alternaria alternata 99 36 36.36 43
Hormodendrum 99 14 14.14 20
Cephalosporium 99 5 5.05 20
Phoma 99 5 5.05 20
Aspergillus flavus 99 4 4.04 20
Fusarium 99 4 4.04 20
Penicillium 99 3 3.03 20
Cephalothecium 99 2 2.02 20
Helminthosporium 99 2 2.02 20
Rhizopus 99 1 1.01 20
Mucor 99 1 1.01 20
Monilia 99 0 0 20
Two CRS patients (†) and 13 control subjects (‡) were not evaluated by SPT.Setomelanomma rostrata (m8). The tree pollen mix
(tx1) was comprised of Acer negundo (t1), Betula verru-
cosa (t3), Quercus alba (t7), Ulmus americana (t8), and
Juglans californica (t10). sIgE was considered detectable
when 65 allergen specific units (kUA/L) were exceeded.
sIgG titers were also measured using ImmunoCAP for a






95% CI p valuepos %pos
5 11.36 3.23 1.16 9.02 0.02
7 15.91 2.19 0.88 5.48 0.09
2 4.55 3.17 0.68 14.72 0.15
0 0 nc nc nc nc
0 0 nc nc nc nc
10 22.73 2.31 1.02 5.19 0.05
4 21.05 1.63 0.50 5.32 0.58
6 13.64 1.71 0.64 4.57 0.35
3 6.98 3.16 0.88 11.34 0.08
3 15.79 1.26 0.33 4.79 1
2 10.53 2.02 0.43 9.49 0.52
3 15 1.09 0.29 4.17 1
0 0 0.82 0.76 0.89 0.36
0 0 0.82 0.75 0.89 0.35
1 5.00 1.45 0.17 12.44 1.00
0 0 0.82 0.75 0.89 0.59
1 5.00 1.01 0.11 9.15 1
0 0 0.83 0.76 0.89 1
1 5.00 0.39 0.03 4.54 0.43
5 11.63 4.34 1.57 12.02 0.003
0 0 0.81 0.74 0.89 0.12
0 0 0.82 0.76 0.89 0.59
0 0 0.82 0.76 0.89 0.59
0 0 0.83 0.76 0.89 1
0 0 0.83 0.76 0.89 1
0 0 0.82 0.76 0.89 1
0 0 0.82 0.76 0.90 1
0 0 0.83 0.76 0.90 1
0 0 0.83 0.77 0.90 1
0 0 0.83 0.77 0.9 1
0 0 nc nc nc nc
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(RGm25). sIgG <0.02 mg/L was considered undetect-
able as previously described [17].
Statistical analysis
The data analysis for this manuscript was generated using
SAS/STAT software, Version 9.1 of the SAS System for
Windows (SAS Institute Inc., Cary, NC, USA). Chi-square
analysis was performed using Fishers Exact option to
determine if the proportion of positive SPT’s were dif-
ferent between groups. Antibody levels were compared
using Analysis of Variance. All differences were consid-
ered significant at p < 0.05.
Results
Of the 158 study participants recruited into the study,
101 had a confirmed clinical history of CRS and 57 control
subjects had a clinical history of CIU but not CRS. In the
CRS group, there were 59 females and 42 males. The age
range was 19–70 and the mean age was 44.5. In the con-
trol group, there were 28 females and 29 males with an
age range 33–61 and the mean age was 47. A total of 31
SPT antigen extracts were tested and 72 out of 99 (73%)
CRS patients and 14 out of 44 (32%) CIU control patients
reacted to at least one SPT extract (data not shown).
The SPT extracts most likely to elicit a positive SPT
response in the CRS population were ragweed (40%), A.
alternata (36%), cat (29%), dust mite (29%), and June
grass (30%; Table 1). In the control population, ragweed
(22%), cat (11%), June grass (21%), and dust mite (16%)
extracts were the most common (Table 1). The SPT re-
activity to the A. alternata extract was 3 fold higher in
CRS compared to the control population. In the sero-
logical analysis, sIgE for the grass mix (21%) and tree
mix (24%) was lower in CRS compared to control pa-
tients; however, there was a greater prevalence of fungal
positive patients in CRS (21%) compared to the control
population (16%) but this was not statistically significant
(Table 2).
In the chi-squared analysis, positive SPT responses to
A. alternata were more prevalent in patients with CRS
compared to controls (odds ratio (OR): 4.34, 95% confi-
dence interval: 1.57, 12.02; Table 1). Sensitization to other





CRS positive CRS ne
n n pos %pos n n po
Grass Mix (gx1) 101 21 20.79 57 13
Mold Mix (mx2) 101 21 20.79 57 9
Tree Mix (tx1) 101 24 23.76 57 15
*Serum IgE titers > 65 kUA/L were interpreted as positive to the tested Phadia Imm3.23, 95% CI: 1.16, 9.02) and ragweed (OR: 2.31, 95% CI:
1.02, 5.19) was additionally identified to be more prevalent
in the CRS group compared to the control group (Table 1).
An elevated OR (1.4) was also observed following the
analysis of IgE ImmunoCAP mold mix serological data;
however, this was not statistically significant (Table 2).
Differences between CRS and control patients were ob-
served for other perennial and seasonal allergen sources
including dog (OR: 3.17, 95% CI: 0.68, 14.72), dust mite
(OR: 2.19, 95% CI: 0.88, 5.48), and timothy grass (OR:
3.16, 95% CI: 0.88, 11.34); however, these differences did
not reach statistical significance and that may be due to
the small sample size (Table 1). No other statistically
significant differences were identified between the other
allergen extracts tested in the SPT and serological analysis
(Table 2).
In the ANOVA analysis of sIgE, the mean allergen spe-
cific units (kUA/L) measured for CRS and CIU control
patients did not vary for grass (p = 0.67), mold (p = 0.34)
or tree mix (p = 0.46) ImmunoCAP antigens (Table 3).
Similarly, there were no statistically significant differ-
ences between mean sIgG titers (mg/mL) in CRS and
control patients for C. herbarum (p = 0.84), A. alternata
(p = 0.92), S. atra (p = 0.13), and A. versicolor (p = 0.22;
Table 4).
Discussion
In this study, 73% of CRS patients had a positive SPT to
at least one of the tested allergen extracts. Sensitization
to A. alternata, cat and ragweed were the most prevalent
sensitizations in CRS patients compared to the control
population. Sensitization to dust mite or timothy grass
was also noted but these results were not statistically sig-
nificant. These results highlight the potential importance
of allergic sensitization to A. alternata and other perennial
or seasonal allergen sources in CRS patients.
The prevalence of CRS patients having at least one
positive SPT (73%) was comparable to results reported
in a study that was located in close proximity (Cleveland,
OH) to Toronto [9]. The identification of increased
prevalence of fungal allergy in CRS was also identified in
Cleveland as well as in southern regions of the United
States [8,14,18] but not in Europe [19]. The serological re-






95% CI p values %pos
22.81 0.89 0.41 1.95 0.84
15.79 1.40 0.59 3.31 0.53
26.32 0.87 0.41 1.84 0.84
unoCap antigen.
Table 3 Analysis of variance of the mean allergen specific units (kUA/L) measured for CRS (n = 101) and control




CRS Positive CRS Negative
F value P valueMean allergen specific
units (kUA/L)
Standard error Mean allergen specific
units (kUA/L)
Standard error
Grass Mix (GX1) 397.37 166.59 517.56 221.76 0.19 0.67
Mold Mix (MX2) 103.03 65.57 206.81 87.28 0.90 0.34
Tree Mix (TX1) 322.45 101.28 198.76 134.81 0.54 0.46
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well as increases in IgE+ cells (mast, plasma cells) in CRS
patients [20,21]. The lack of concordance between SPT
and serological studies in CRS patients may be due to
increased sensitivity of SPT but also the variability of aller-
gen extracts, as well as concurrent exposure of the sub-
jects to antigens derived from a varying spectrum of
perennial and seasonal allergen sources (tree, grass, insect,
and fungal) [9]. Allergic sensitization to staphylococcal
and streptococcal toxins has been found to be as high as
78% in CRS patients [22]. While these factors were not
evaluated in the present study, they could also influence
the pathology and prevalence of sensitization in CRS
patients. Taking these limitations into consideration, the
results of the present study suggest that evidence of aller-
gic sensitization, in particular fungal hypersensitivity,
could potentially be used as diagnostic criteria for CRS
[8,18]. Currently, the Canadian clinical practice guidelines
for CRS recognize allergy testing in cases of CRS but the
guidelines do not recognize specific allergens [4].
In the present study, 36% of the CRS study partici-
pants were sensitized to A. alternata. These SPT results
are comparable to other studies that have identified
sensitization to Alternaria in CRS patients [20]. A. alter-
nata has been previously implicated in cases of CRS in the
United States [20] and it is among the most ubiquitous
phyloplane fungal species in Toronto [23,24]. The pres-
ence of A. alternata conidia in the upper respiratory tract
has been demonstrated in microscopic and immunologic
studies of allergic mucin derived from CRS subjects
[25-27]. In vitro studies have also shown that A. alternata
extracts induce the recruitment of eosinophils, induce
interferon-y, IL-5 and IL-13 in peripheral blood mono-
nuclear cells [20,28]; and regulates the expression of sur-
factant protein D and LL-37 in fungal sensitized CRSTable 4 Analysis of variance of the mean IgG titer (mg/mL) m
IgG ImmunoCap Antigen
CRS Positive
Mean IgG (mg/mL) Standard error
Cladosporium herbarum (GM2) 31.18 3.47
Alternaria alternata (GM6) 5.05 0.42
Stachybotrys atra (RGM24) 4.75 0.39
Aspergillus versicolor (RGM25) 23.76 2.66patients [29,30]. It has been hypothesized that allergens
released from Alternaria conidia and germinating co-
nidia may have a functional role in CRS but this has
remained controversial and is the subject of continued
research [8,31].
Sensitization to cat and ragweed were additionally
identified as prevalent sensitizations in the present
study, and sensitization to these allergens has been
previously reported in a CRS study in Washington
D.C. [32]. Cat allergy is an important source of per-
ennial allergen in inner city environments. Interest-
ingly, Canadian aerobiological surveys have shown
that the highest concentration of ragweed pollen occur
in southern Ontario [33].
Our results deviate from previous studies that have
identified dust mite to be an important perennial aller-
gen associated with CRS [9,13,19,34]. Gutman and col-
leagues identified 73% of CRS patients in Cleveland to
be sensitized to dust mite [9]. A study of 200 patients in
San Francisco who had undergone functional endoscopic
sinus surgery for chronic or recurrent rhinosinusitis
showed that 22% were sensitized to house dust mite
[13]. Freudenberger et al. [34] also identified 68% of
CRS patients in New York to exhibit a positive immedi-
ate skin test reaction to dust mite extract. Although
dust mite sensitization can be as high as 60% in Toronto
[35], the prevalence of sensitization to dust mite only
approached 30% in the present study and was not more
prevalent in patients with CRS. To date, the role of sea-
sonal and perennial allergy in CRS requires further
evaluation; however, the results of this study suggest
that in addition to Alternaria, cat and ragweed allergens
may additionally contribute to swelling and blockage of
sinus ostia leading to mucous buildup, secondary infec-
tion, and the development of CRS [4].easured for CRS (n = 101) and control patients (n = 57)
CRS Negative
F value P value
Mean IgG (mg/mL) Standard error
32.33 4.62 0.04 0.84
4.98 0.56 0.01 0.92
3.76 0.51 2.36 0.13
18.54 3.41 1.53 0.22
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design of this study that should be considered when
interpreting these results. The association of other sea-
sonal and perennial allergens to CRS such as dust mite,
dog and timothy grass may have been identified if a larger
number of study participants and controls were recruited
into the study. Selection and recruitment of patients in-
cluded CRS patients with and without nasal polyps and
allergic fungal sinusitis which may have resulted in the
over estimation of allergic sensitization in this popula-
tion of Canadian CRS patients [10,11,36]. However, our
objective was to study the overall prevalence of allergy
sensitization in CRS. Geographic variability in CRS and
allergic sensitization are also variables that may have in-
fluenced the results of this study [5,6]. Surveys of CRS
in Canada have shown a greater prevalence of CRS in
eastern provinces, in particular Nova Scotia [5]. We
hypothesize that the allergen burden in Nova Scotia
may differ to the Toronto metropolitan environment
due to a varying spectrum of tree, grass, weed, insect
and mold allergens and as a result, the profile of allergic
sensitization may vary substantially. Future studies should
include larger patient numbers and utilize a wider panel of
perennial and seasonal allergens that reflect the allergen
burden of the local study environment.Conclusions
In conclusion, the results of this study demonstrate a gen-
eral association between CRS and allergic sensitization. In
the Toronto metropolitan area, A. alternata was promin-
ent but cat and ragweed allergens were also associated
with CRS. Taken together, these results suggest exposure
to regionally specific allergens may drive a process result-
ing in CRS in some patients, perhaps with a genetic pre-
disposition or epidermal barrier dysfunction. Future
studies should be designed in other regions of Canada
to identify and characterize the specific sensitization
profiles of CRS patients.Competing interests
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